UCADH Section Psychobiology of Reproduction, Mother Infant Dept, Univ. of Modena & Reggio Emilia, Emilia, Modena, Italy.
Gynecol Endocrinol. 2010 Oct;26(10):773-9. doi: 10.3109/09513590.2010.487607.
Migraine attacks are common in the perimenstrual period (menstrually-related migraine, MRM) and can be particularly exacerbated by the cyclic suspension of oral contraceptives (oral contraceptive-induced menstrual migraine, OCMM). This cross-over, randomised study evaluated the efficacy and tolerability of rectal (25 mg) and oral (50 mg) sumatriptan in the treatment of 232 menstrual migraine attacks (135 MRM and 97 OCMM). Two hours after suppository administration, 72% of patients in the MRM group achieved pain relief and 24% were pain free; after tablet administration, the percentages were 66% and 27%, respectively. In the OCMM group 55% of patients improved at 2 h with suppositories and 46% with tablets, 27% of patients were pain-free after suppositories and 18% after tablets. Fifty percent of patients given suppositories were pain-free at 4 h post-treatment and 47% of those given tablets. Sumatriptan also effectively alleviated symptoms associated with migraine, such as nausea, vomiting and photo/phonophobia. A single dose of medication sufficed for pain relief without relapse in 47.4% of the attacks (MRM: 66%; OCMM: 33%). Both formulations were well tolerated.
偏头痛发作在经期前后很常见（与月经相关的偏头痛，MRM），并且口服避孕药的周期性停药可能会使其恶化（口服避孕药引起的月经性偏头痛，OCMM）。这项交叉、随机研究评估了直肠（25 毫克）和口服（50 毫克）舒马曲坦治疗 232 例月经性偏头痛发作（135 例 MRM 和 97 例 OCMM）的疗效和耐受性。栓剂给药后 2 小时，MRM 组 72%的患者疼痛缓解，24%的患者无疼痛；给药后 2 小时，片剂组的这两个比例分别为 66%和 27%。在 OCMM 组中，55%的患者用栓剂在 2 小时内改善，46%的患者用片剂改善，27%的患者用栓剂无疼痛，18%的患者用片剂无疼痛。50%的给予栓剂的患者在治疗后 4 小时无疼痛，47%的给予片剂的患者无疼痛。舒马曲坦还能有效缓解偏头痛相关症状，如恶心、呕吐和畏光/畏声。47.4%的发作（MRM：66%；OCMM：33%）仅需单次用药即可缓解疼痛而不复发。两种制剂均具有良好的耐受性。
